<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00957359</url>
  </required_header>
  <id_info>
    <org_study_id>06-954</org_study_id>
    <nct_id>NCT00957359</nct_id>
  </id_info>
  <brief_title>Psilocybin Cancer Anxiety Study</brief_title>
  <official_title>Effects of Psilocybin on Anxiety and Psychosocial Distress in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this double-blind, placebo-controlled pilot study is to assess the
      efficacy of psilocybin administration (4-phosphoryloxy-N,N-dimethyltryptamine), a
      serotonergic psychoactive agent, on psychosocial distress, with the specific primary outcome
      variable being anxiety associated with cancer. Secondary outcome measures will look at the
      effect of psilocybin on symptoms of pain perception, depression, existential/psychospiritual
      distress, attitudes towards disease progression and death, quality of life, and
      spiritual/mystical states of consciousness. In addition, a secondary objective of the study
      is to determine the feasibility of administering psilocybin to this patient population, with
      regards to the following issues: safety, patient recruitment, consent for treatment, and
      retention. The duration of the proposed investigation will be long enough to administer the
      drug one time to each of thirty-two patients and to conduct follow-up assessments. This study
      is separate but similar to a recently completed study at the Los Angeles Biomedical Research
      Institute at Harbor-UCLA Medical Center, run by a psychiatrist, Dr. Charles Grob. Although
      the outcomes measures would be similar to those used as in the Grob study, the proposed dose
      of psilocybin is higher at 0.3mg/kg and the total subjects for the study would be 32 instead
      of 12. The study utilizes a cross-over design at 7 weeks and includes prospective follow-up
      of 6 months duration. This study has been approved by the Bellevue Psychiatry Research
      Committee, the NYU Oncology PRMC Committee, the Food and Drug Administration (FDA) through
      the issuance of an IND (77,138), the New York University School of Medicine Institutional
      Review Board (NYU IRB), the Health and Hospitals Corporation (HHC)-New York University (NYU)
      Clinical Translational Science Institute (CTSI), the NYU Bluestone Center for Clinical
      Research, and the Drug Enforcement Agency (DEA) through the issuance of a schedule I license.

      It is hypothesized that a one time experience with psilocybin will occasion dramatic shifts
      in consciousness and awareness that will lead to short-term (ie hours to days) and long-term
      (up to 6 months in this study, following the administration of the second dosing, either
      psilocybin or placebo) improvement in anxiety, depression, and pain associated with advanced
      cancer. The exact mechanism of action is unclear but based on studies done in the 60's using
      serotonergic hallucinogens in patients with advanced cancer, improvements in anxiety levels,
      mood and pain were reported. However, a treatment model developed by the famous British
      psychiatrist Humphrey Osmond, offers one possibility. In this model, serotonergic
      hallucinogens' therapeutic mechanism lies in their ability to allow the individual to access
      novel dimensions of consciousness and their efficacy or lack thereof relies on whether a
      transcendent and mystical state of awareness is attained. Another possible mechanism relates
      to what Dobkin de Rios and Grob have described as 'managed altered states of consciousness,'
      where the power of suggestibility, occurring in a safe setting, allows one to transcend a
      particular state of consciousness (i.e. anxiety and depression associated with advanced
      illness) as a means to facilitate emotional discharge and to manage irreconcilable conflict.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2009</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HADS Anxiety</measure>
    <time_frame>2-4 weeks prior to drug administration</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HADS Anxiety</measure>
    <time_frame>1 day prior to drug administration 1</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HADS Anxiety</measure>
    <time_frame>1 day post drug administration 1</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HADS Anxiety</measure>
    <time_frame>6 weeks post drug administration 1</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HADS Anxiety</measure>
    <time_frame>1 day prior to drug administration 2</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HADS Anxiety</measure>
    <time_frame>6 weeks post drug administration 2</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HADS Anxiety</measure>
    <time_frame>26 weeks post drug administration 2</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>State-Trait Anxiety Inventory (STAI) State</measure>
    <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
    <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAI State</measure>
    <time_frame>1 day prior to drug administration 1</time_frame>
    <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAI State</measure>
    <time_frame>1 day post drug administration 1</time_frame>
    <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HADS Depression</measure>
    <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
    <description>0-21 (higher score more depression)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAI State</measure>
    <time_frame>6 weeks post drug administration 1</time_frame>
    <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAI State</measure>
    <time_frame>1 day prior to drug administration 2</time_frame>
    <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAI State</measure>
    <time_frame>1 day post drug administration 2</time_frame>
    <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAI State</measure>
    <time_frame>6 weeks post drug administration 2</time_frame>
    <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAI State</measure>
    <time_frame>26 weeks post drug administration 2</time_frame>
    <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAI Trait</measure>
    <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
    <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAI Trait</measure>
    <time_frame>1 day prior to drug administration 1</time_frame>
    <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAI Trait</measure>
    <time_frame>1 day post drug administration 1</time_frame>
    <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAI Trait</measure>
    <time_frame>6 weeks post drug administration 1</time_frame>
    <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAI Trait</measure>
    <time_frame>1 day prior to drug administration 2</time_frame>
    <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAI Trait</measure>
    <time_frame>1 day post drug administration 2</time_frame>
    <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAI Trait</measure>
    <time_frame>6 weeks prior to drug administration 2</time_frame>
    <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAI Trait</measure>
    <time_frame>6 weeks post drug administration 2</time_frame>
    <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HADS Depression</measure>
    <time_frame>1 day prior to drug administration 1</time_frame>
    <description>0-21 (higher score more depression)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HADS Depression</measure>
    <time_frame>1 day post drug administration 1</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS) used for measuring depression; Scored on a scale of 0-21 (higher score more depression)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HADS Depression</measure>
    <time_frame>6 weeks post drug administration 1</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS) used for measuring depression; Scored on a scale of 0-21 (higher score more depression)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HADS Anxiety</measure>
    <time_frame>1 day post drug administration 2</time_frame>
    <description>0-21 (higher score more anxiety)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HADS Depression</measure>
    <time_frame>1 day post drug administration 2</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS) used for measuring depression; Scored on a scale of 0-21 (higher score more depression)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HADS Depression</measure>
    <time_frame>6 weeks post drug administration 2</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS) used for measuring depression; Scored on a scale of 0-21 (higher score more depression)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HADS Depression</measure>
    <time_frame>26 weeks post drug administration 2</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS) used for measuring depression; Scored on a scale of 0-21 (higher score more depression)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death Anxiety Scale</measure>
    <time_frame>26 weeks post drug administration 2</time_frame>
    <description>0-15 (higher score more death anxiety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death Anxiety Scale</measure>
    <time_frame>2 weeks post drug administration 1</time_frame>
    <description>0-15 (higher score more death anxiety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death Transcendence Scale</measure>
    <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
    <description>0-60 (higher score more death transcendence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hopelessness</measure>
    <time_frame>Baseline</time_frame>
    <description>0-16 (higher score more hopeless)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death Anxiety Scale</measure>
    <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
    <description>0-15 (higher score more death anxiety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death Transcendence Scale</measure>
    <time_frame>2 weeks post drug administration 1</time_frame>
    <description>0-60 (higher score more death transcendence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hopelessness</measure>
    <time_frame>2 weeks post drug administration 1</time_frame>
    <description>0-16 (higher score more hopeless)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hopelessness</measure>
    <time_frame>26 weeks post drug administration 2</time_frame>
    <description>0-16 (higher score more hopeless)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demoralization Scale</measure>
    <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
    <description>0-96 (higher score more demoralized)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demoralization Scale</measure>
    <time_frame>2 weeks post drug administration 1</time_frame>
    <description>0-96 (higher score more demoralized)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demoralization Scale</measure>
    <time_frame>26 weeks post drug administration 2</time_frame>
    <description>0-96 (higher score more demoralized)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL Physical Health Scale</measure>
    <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
    <description>4-20 (higher score improved quality of life domain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL Physical Health Scale</measure>
    <time_frame>2 weeks post drug administration 1</time_frame>
    <description>4-20 (higher score improved quality of life domain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL Physical Health Scale</measure>
    <time_frame>26 weeks post drug administration 2</time_frame>
    <description>4-20 (higher score improved quality of life domain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL Psychological Scale</measure>
    <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
    <description>4-20 (higher score improved quality of life domain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL Psychological Scale</measure>
    <time_frame>2 weeks post drug administration 1</time_frame>
    <description>4-20 (higher score improved quality of life domain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL Psychological Scale</measure>
    <time_frame>26 weeks post drug administration 2</time_frame>
    <description>4-20 (higher score improved quality of life domain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL Social Relationships Scale</measure>
    <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
    <description>4-20 (higher score improved quality of life domain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL Social Relationships Scale</measure>
    <time_frame>2 weeks post drug administration 1</time_frame>
    <description>4-20 (higher score improved quality of life domain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL Social Relationships Scale</measure>
    <time_frame>26 weeks post drug administration 2</time_frame>
    <description>4-20 (higher score improved quality of life domain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL Environment Scale</measure>
    <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
    <description>4-20 (higher score improved quality of life domain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL Environment Scale</measure>
    <time_frame>2 weeks post drug administration 1</time_frame>
    <description>4-20 (higher score improved quality of life domain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL Environment Scale</measure>
    <time_frame>26 weeks post drug administration 2</time_frame>
    <description>4-20 (higher score improved quality of life domain)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Psilocybin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Niacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psilocybin</intervention_name>
    <description>Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg</description>
    <arm_group_label>Niacin</arm_group_label>
    <arm_group_label>Psilocybin</arm_group_label>
    <other_name>4-phosphoryloxy-N,N-dimethyltryptamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin</intervention_name>
    <description>Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
    <arm_group_label>Niacin</arm_group_label>
    <arm_group_label>Psilocybin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-76

          -  Current or historical diagnosis of cancer

          -  Projected life expectancy of at least one year

          -  DSM-IV diagnoses: Acute Stress Disorder, Generalized Anxiety Disorder, Anxiety
             Disorder due to cancer, Adjustment Disorder with anxious features

          -  Any stage of cancer diagnosis

        Exclusion Criteria:

          -  Epilepsy

          -  Renal disease

          -  Diabetes

          -  Abnormal liver function

          -  Severe cardiovascular disease

          -  Malignant Hypertension

          -  Baseline blood pressure must be less than or equal to 140/90

          -  Personal history or immediate family members with schizophrenia, bipolar affective
             disorder, delusional disorder, schizoaffective disorder or other psychotic spectrum
             illness

          -  Current substance use disorder

          -  Medication contraindications: anti-seizures medications, insulin, oral hypoglycemics,
             clonidine, aldomet, cardiovascular medications, anti-psychotics (first and second
             generation), anti-depressants and mood stabilizers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Ross, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony Bossis, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Co-Principal Investigator NYU Langone School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Guss, MD</last_name>
    <role>Study Director</role>
    <affiliation>Co-Principal Investigator NYU Langone School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU College of Dentistry Bluestone Center for Clinical Research</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nyucanceranxiety.org/</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 11, 2009</study_first_submitted>
  <study_first_submitted_qc>August 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2009</study_first_posted>
  <results_first_submitted>February 19, 2019</results_first_submitted>
  <results_first_submitted_qc>October 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 3, 2019</results_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Depression</keyword>
  <keyword>Hallucinogens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Psilocybin</mesh_term>
    <mesh_term>N,N-Dimethyltryptamine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT00957359/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Psilocybin First, Then Niacin</title>
          <description>Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg.</description>
        </group>
        <group group_id="P2">
          <title>Niacin First, Then Psilocybin</title>
          <description>Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Psilocybin First, Then Niacin</title>
          <description>Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg</description>
        </group>
        <group group_id="B2">
          <title>Niacin First, Then Psilocybin</title>
          <description>Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="15.03"/>
                    <measurement group_id="B2" value="60.27" spread="9.45"/>
                    <measurement group_id="B3" value="56.28" spread="12.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HADS Anxiety</title>
        <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
        <time_frame>2-4 weeks prior to drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>HADS Anxiety</title>
          <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.14" spread="1.88"/>
                    <measurement group_id="O2" value="16.93" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HADS Anxiety</title>
        <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
        <time_frame>1 day prior to drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>HADS Anxiety</title>
          <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread=".83"/>
                    <measurement group_id="O2" value="9.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HADS Anxiety</title>
        <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
        <time_frame>1 day post drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>HADS Anxiety</title>
          <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" spread=".83"/>
                    <measurement group_id="O2" value="6.0" spread=".80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HADS Anxiety</title>
        <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
        <time_frame>6 weeks post drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>HADS Anxiety</title>
          <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.64" spread=".83"/>
                    <measurement group_id="O2" value="8.44" spread=".82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HADS Anxiety</title>
        <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
        <time_frame>1 day prior to drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>HADS Anxiety</title>
          <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.57" spread="0.88"/>
                    <measurement group_id="O2" value="7.98" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HADS Anxiety</title>
        <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
        <time_frame>6 weeks post drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>HADS Anxiety</title>
          <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread=".90"/>
                    <measurement group_id="O2" value="5.54" spread=".89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HADS Anxiety</title>
        <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
        <time_frame>26 weeks post drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>HADS Anxiety</title>
          <description>Hospital Anxiety and Depression Scale (HADS) used for measuring anxiety; Scored on a scale of 0-21 (higher score more anxiety)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" spread=".92"/>
                    <measurement group_id="O2" value="4.70" spread=".89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>State-Trait Anxiety Inventory (STAI) State</title>
        <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
        <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>State-Trait Anxiety Inventory (STAI) State</title>
          <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.79" spread="2.83"/>
                    <measurement group_id="O2" value="48.53" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAI State</title>
        <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
        <time_frame>1 day prior to drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>STAI State</title>
          <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.07" spread="2.83"/>
                    <measurement group_id="O2" value="45.6" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAI State</title>
        <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
        <time_frame>1 day post drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>STAI State</title>
          <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="2.83"/>
                    <measurement group_id="O2" value="40.33" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HADS Depression</title>
        <description>0-21 (higher score more depression)</description>
        <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>HADS Depression</title>
          <description>0-21 (higher score more depression)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" spread="0.92"/>
                    <measurement group_id="O2" value="7" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAI State</title>
        <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
        <time_frame>6 weeks post drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>STAI State</title>
          <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" spread="2.83"/>
                    <measurement group_id="O2" value="47.05" spread="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAI State</title>
        <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
        <time_frame>1 day prior to drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>STAI State</title>
          <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.72" spread="2.99"/>
                    <measurement group_id="O2" value="45.31" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAI State</title>
        <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
        <time_frame>1 day post drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>STAI State</title>
          <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.73" spread="3.04"/>
                    <measurement group_id="O2" value="38.11" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAI State</title>
        <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
        <time_frame>6 weeks post drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>STAI State</title>
          <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.67" spread="3.05"/>
                    <measurement group_id="O2" value="37.77" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAI State</title>
        <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
        <time_frame>26 weeks post drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>STAI State</title>
          <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.04" spread="3.15"/>
                    <measurement group_id="O2" value="38.28" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAI Trait</title>
        <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
        <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>STAI Trait</title>
          <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.79" spread="2.83"/>
                    <measurement group_id="O2" value="48.53" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAI Trait</title>
        <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
        <time_frame>1 day prior to drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>STAI Trait</title>
          <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.07" spread="2.83"/>
                    <measurement group_id="O2" value="45.87" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAI Trait</title>
        <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
        <time_frame>1 day post drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>STAI Trait</title>
          <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="2.83"/>
                    <measurement group_id="O2" value="44" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAI Trait</title>
        <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
        <time_frame>6 weeks post drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>STAI Trait</title>
          <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" spread="2.83"/>
                    <measurement group_id="O2" value="46.19" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAI Trait</title>
        <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
        <time_frame>1 day prior to drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>STAI Trait</title>
          <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.72" spread="2.99"/>
                    <measurement group_id="O2" value="45.31" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAI Trait</title>
        <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
        <time_frame>1 day post drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>STAI Trait</title>
          <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.73" spread="3.04"/>
                    <measurement group_id="O2" value="38.11" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAI Trait</title>
        <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
        <time_frame>6 weeks prior to drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>STAI Trait</title>
          <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.67" spread="3.05"/>
                    <measurement group_id="O2" value="37.77" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAI Trait</title>
        <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
        <time_frame>6 weeks post drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>STAI Trait</title>
          <description>STAI scores 20-80 (higher score more anxiety). Commonly classified as &quot;no or low anxiety&quot; (20-37), &quot;moderate anxiety&quot; (38-44), and &quot;high anxiety&quot; (45-80).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.04" spread="3.15"/>
                    <measurement group_id="O2" value="38.28" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HADS Depression</title>
        <description>0-21 (higher score more depression)</description>
        <time_frame>1 day prior to drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>HADS Depression</title>
          <description>0-21 (higher score more depression)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.43" spread="1.88"/>
                    <measurement group_id="O2" value="16.47" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HADS Depression</title>
        <description>Hospital Anxiety and Depression Scale (HADS) used for measuring depression; Scored on a scale of 0-21 (higher score more depression)</description>
        <time_frame>1 day post drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>HADS Depression</title>
          <description>Hospital Anxiety and Depression Scale (HADS) used for measuring depression; Scored on a scale of 0-21 (higher score more depression)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" spread="1.88"/>
                    <measurement group_id="O2" value="12.07" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HADS Depression</title>
        <description>Hospital Anxiety and Depression Scale (HADS) used for measuring depression; Scored on a scale of 0-21 (higher score more depression)</description>
        <time_frame>6 weeks post drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>HADS Depression</title>
          <description>Hospital Anxiety and Depression Scale (HADS) used for measuring depression; Scored on a scale of 0-21 (higher score more depression)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="1.88"/>
                    <measurement group_id="O2" value="14.24" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HADS Anxiety</title>
        <description>0-21 (higher score more anxiety)</description>
        <time_frame>1 day post drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>HADS Anxiety</title>
          <description>0-21 (higher score more anxiety)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.84" spread="0.69"/>
                    <measurement group_id="O2" value="13.02" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HADS Depression</title>
        <description>Hospital Anxiety and Depression Scale (HADS) used for measuring depression; Scored on a scale of 0-21 (higher score more depression)</description>
        <time_frame>1 day post drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>HADS Depression</title>
          <description>Hospital Anxiety and Depression Scale (HADS) used for measuring depression; Scored on a scale of 0-21 (higher score more depression)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.25" spread="1.97"/>
                    <measurement group_id="O2" value="10.05" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HADS Depression</title>
        <description>Hospital Anxiety and Depression Scale (HADS) used for measuring depression; Scored on a scale of 0-21 (higher score more depression)</description>
        <time_frame>6 weeks post drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>HADS Depression</title>
          <description>Hospital Anxiety and Depression Scale (HADS) used for measuring depression; Scored on a scale of 0-21 (higher score more depression)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.31" spread="1.99"/>
                    <measurement group_id="O2" value="9.65" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HADS Depression</title>
        <description>Hospital Anxiety and Depression Scale (HADS) used for measuring depression; Scored on a scale of 0-21 (higher score more depression)</description>
        <time_frame>26 weeks post drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>HADS Depression</title>
          <description>Hospital Anxiety and Depression Scale (HADS) used for measuring depression; Scored on a scale of 0-21 (higher score more depression)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.48" spread="2.04"/>
                    <measurement group_id="O2" value="9.06" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death Anxiety Scale</title>
        <description>0-15 (higher score more death anxiety)</description>
        <time_frame>26 weeks post drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>Death Anxiety Scale</title>
          <description>0-15 (higher score more death anxiety)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.71" spread="0.72"/>
                    <measurement group_id="O2" value="6.83" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death Anxiety Scale</title>
        <description>0-15 (higher score more death anxiety)</description>
        <time_frame>2 weeks post drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>Death Anxiety Scale</title>
          <description>0-15 (higher score more death anxiety)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.57" spread="0.67"/>
                    <measurement group_id="O2" value="7.85" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death Transcendence Scale</title>
        <description>0-60 (higher score more death transcendence)</description>
        <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>Death Transcendence Scale</title>
          <description>0-60 (higher score more death transcendence)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.64" spread="5.96"/>
                    <measurement group_id="O2" value="11.27" spread="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hopelessness</title>
        <description>0-16 (higher score more hopeless)</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>Hopelessness</title>
          <description>0-16 (higher score more hopeless)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71" spread="0.76"/>
                    <measurement group_id="O2" value="6.73" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death Anxiety Scale</title>
        <description>0-15 (higher score more death anxiety)</description>
        <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>Death Anxiety Scale</title>
          <description>0-15 (higher score more death anxiety)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.14" spread="0.67"/>
                    <measurement group_id="O2" value="8.13" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death Transcendence Scale</title>
        <description>0-60 (higher score more death transcendence)</description>
        <time_frame>2 weeks post drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>Death Transcendence Scale</title>
          <description>0-60 (higher score more death transcendence)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.98" spread="6.44"/>
                    <measurement group_id="O2" value="19.88" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hopelessness</title>
        <description>0-16 (higher score more hopeless)</description>
        <time_frame>2 weeks post drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>Hopelessness</title>
          <description>0-16 (higher score more hopeless)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" spread="0.76"/>
                    <measurement group_id="O2" value="6.08" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hopelessness</title>
        <description>0-16 (higher score more hopeless)</description>
        <time_frame>26 weeks post drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>Hopelessness</title>
          <description>0-16 (higher score more hopeless)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" spread="0.82"/>
                    <measurement group_id="O2" value="3.86" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Demoralization Scale</title>
        <description>0-96 (higher score more demoralized)</description>
        <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>Demoralization Scale</title>
          <description>0-96 (higher score more demoralized)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.71" spread="3.61"/>
                    <measurement group_id="O2" value="38.07" spread="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Demoralization Scale</title>
        <description>0-96 (higher score more demoralized)</description>
        <time_frame>2 weeks post drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>Demoralization Scale</title>
          <description>0-96 (higher score more demoralized)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.79" spread="3.61"/>
                    <measurement group_id="O2" value="32.79" spread="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Demoralization Scale</title>
        <description>0-96 (higher score more demoralized)</description>
        <time_frame>26 weeks post drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>Demoralization Scale</title>
          <description>0-96 (higher score more demoralized)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.38" spread="3.93"/>
                    <measurement group_id="O2" value="24.58" spread="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QoL Physical Health Scale</title>
        <description>4-20 (higher score improved quality of life domain)</description>
        <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>QoL Physical Health Scale</title>
          <description>4-20 (higher score improved quality of life domain)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.14" spread="0.94"/>
                    <measurement group_id="O2" value="12.53" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QoL Physical Health Scale</title>
        <description>4-20 (higher score improved quality of life domain)</description>
        <time_frame>2 weeks post drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>QoL Physical Health Scale</title>
          <description>4-20 (higher score improved quality of life domain)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="0.94"/>
                    <measurement group_id="O2" value="12.44" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QoL Physical Health Scale</title>
        <description>4-20 (higher score improved quality of life domain)</description>
        <time_frame>26 weeks post drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>QoL Physical Health Scale</title>
          <description>4-20 (higher score improved quality of life domain)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.77" spread="1.05"/>
                    <measurement group_id="O2" value="14.14" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QoL Psychological Scale</title>
        <description>4-20 (higher score improved quality of life domain)</description>
        <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>QoL Psychological Scale</title>
          <description>4-20 (higher score improved quality of life domain)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.57" spread=".66"/>
                    <measurement group_id="O2" value="12.67" spread=".64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QoL Psychological Scale</title>
        <description>4-20 (higher score improved quality of life domain)</description>
        <time_frame>2 weeks post drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>QoL Psychological Scale</title>
          <description>4-20 (higher score improved quality of life domain)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.43" spread=".66"/>
                    <measurement group_id="O2" value="12.28" spread=".66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QoL Psychological Scale</title>
        <description>4-20 (higher score improved quality of life domain)</description>
        <time_frame>26 weeks post drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>QoL Psychological Scale</title>
          <description>4-20 (higher score improved quality of life domain)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.78" spread=".74"/>
                    <measurement group_id="O2" value="14.90" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QoL Social Relationships Scale</title>
        <description>4-20 (higher score improved quality of life domain)</description>
        <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>QoL Social Relationships Scale</title>
          <description>4-20 (higher score improved quality of life domain)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.62" spread=".85"/>
                    <measurement group_id="O2" value="13.24" spread=".82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QoL Social Relationships Scale</title>
        <description>4-20 (higher score improved quality of life domain)</description>
        <time_frame>2 weeks post drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>QoL Social Relationships Scale</title>
          <description>4-20 (higher score improved quality of life domain)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.86" spread=".85"/>
                    <measurement group_id="O2" value="12.78" spread=".85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QoL Social Relationships Scale</title>
        <description>4-20 (higher score improved quality of life domain)</description>
        <time_frame>26 weeks post drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>QoL Social Relationships Scale</title>
          <description>4-20 (higher score improved quality of life domain)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread=".95"/>
                    <measurement group_id="O2" value="13.71" spread=".95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QoL Environment Scale</title>
        <description>4-20 (higher score improved quality of life domain)</description>
        <time_frame>2-4 weeks prior to drug administration/ Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>QoL Environment Scale</title>
          <description>4-20 (higher score improved quality of life domain)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.75" spread=".74"/>
                    <measurement group_id="O2" value="14.93" spread=".71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QoL Environment Scale</title>
        <description>4-20 (higher score improved quality of life domain)</description>
        <time_frame>2 weeks post drug administration 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>QoL Environment Scale</title>
          <description>4-20 (higher score improved quality of life domain)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.42" spread="0.74"/>
                    <measurement group_id="O2" value="13.90" spread=".74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QoL Environment Scale</title>
        <description>4-20 (higher score improved quality of life domain)</description>
        <time_frame>26 weeks post drug administration 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Psilocybin First, Then Niacin</title>
            <description>Drug intervention
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
          <group group_id="O2">
            <title>Niacin First, Then Psilocybin</title>
            <description>Active control
Psilocybin: Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
Niacin: Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
          </group>
        </group_list>
        <measure>
          <title>QoL Environment Scale</title>
          <description>4-20 (higher score improved quality of life domain)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.96" spread=".82"/>
                    <measurement group_id="O2" value="15.82" spread=".82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Psilocybin</title>
          <description>Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
        </group>
        <group group_id="E2">
          <title>Niacin</title>
          <description>Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>elevations in BP and HR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Transient Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephen Ross, MD</name_or_title>
      <organization>NYU Langone Health</organization>
      <phone>212-263-7264</phone>
      <email>Stephen.Ross@nyulangone.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

